This study evaluated the efficacy and safety of lisdexamfetamine dimesylate (LDX) for binge eating disorder (BED) in adults. Participants were randomized to placebo or LDX doses of 30, 50, or 70 mg/day for 11 weeks. The primary outcome was reduction in binge eating days per week. Secondary outcomes included reductions in binge episodes, improvements on the Binge Eating Scale and Three-Factor Eating Questionnaire. LDX at 50 and 70 mg/day significantly reduced binge eating days and episodes compared to placebo. LDX also improved binge eating behaviors and attitudes on secondary measures. The most common side effects with LDX were decreased appetite, dry mouth, headache,